drugset / Trial / NCT06047197
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma
Timeline
- Start
- 2023-09-05
- Primary completion
- 2026-09-05
- Completion
- 2026-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC19D2 | Cell therapy | 500000 cells/kg | — |
| Subject | RC19D2 | Cell therapy | 1e+06 cells/kg | — |
| Subject | RC19D2 | Cell therapy | 2.5e+06 cells/kg | — |
| Subject | RC19D2 | Cell therapy | 5e+06 cells/kg | — |